JERUSALEM & MIAMI--(BUSINESS WIRE)--Dec. 22, 2005--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) and IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that, as expected, they have signed a consent order for submission to the U.S. Federal Trade Commission (“FTC”) in connection with the pending acquisition of IVAX by Teva. The scope of the consent order is consistent with what the parties have anticipated throughout the FTC review process. Completion of the FTC review process is the last remaining regulatory condition to the consummation of the transaction.
